Company: WHWK
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001193125-25-268895
Chunk: 9

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Item 8
Chunk 9
---
 100% of the outstanding shares of capital stock of Aadi Subsidiary from the Company for a cash payment of $102.4 million (following applicable purchase price adjustments under the Divestiture Agreement) (the "FYARRO Divestiture"). The FYARRO Divestiture closed on March 25, 2025 and, as a result, the Company no longer operates the FYARRO Business.Company Name Change. In connection with the FYARRO Divestiture, the Company changed its name from "Aadi Bioscience, Inc." to "Whitehawk Therapeutics, Inc." and the Company changed its ticker symbol on the Nasdaq Capital Market to "WHWK". Merger with Aerpio Pharmaceuticals, Inc.On August 26, 2021 (the “Closing Date”), the Company completed its business combination with Aadi Subsidiary (then a private company known as Aadi Bioscience, Inc.) (“Private Aadi”), in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated May 16, 2021, by and among the Company, Aspen Merger Subsidiary, Inc. (“Merger Sub”) and Private Aadi (the “Merger Agreement”), pursuant to which Merger Sub merged with and into Private Aadi, with Private Aadi surviving as a wholly owned subsidiary of the Company (the “Reverse Merger”) until the FYARRO Divestiture.